Kristine A. Frerichs

Author

Vrije Universiteit Amsterdam ORCID

Also Known As

K. Frerichs, Kristine A. Frerichs, Kristine Aileen Frerichs, Kristine Frerichs

Publications

888

Citations

H-Index

Concepts

All Affiliations

Vrije Universiteit Amsterdam Amsterdam University Medical Centers University Medical Center Utrecht Janssen (United States)Meander Medisch Centrum

About

Kristine A. Frerichs is an author at Vrije Universiteit Amsterdam specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	113
2	Immunology	3	3	113
3	Health Sciences	1	1	13
4	Allergy	1	1	60
5	Neurology	1	1	13

Kristine A. Frerichs

Publications

724

Citations

H-Index

Page 1

	Year	Citations
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma Christie P.M. Verkleij, Marloes E.C. Broekmans, Mark van Duin, Blood Advances	2021	153
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence Afroditi Katsarou, Maria Sjöstrand, Jyoti Naik, Science Translational Medicine	2021	114
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab Kristine A. Frerichs, Marloes E.C. Broekmans, Jhon A. Marin Soto, Clinical Cancer Research	2020	85
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos, Blood Advances Humoral ResponseImmunologyImmunoeditingPathologyImmunotherapy	2023	60
T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma Christie P.M. Verkleij, Chloe O’Neill, Marloes E.C. Broekmans, Clinical Cancer Research	2024	43
Efficacy and safety of daratumumab combined with all-<i>trans</i>retinoic acid in relapsed/refractory multiple myeloma Kristine A. Frerichs, Monique C. Minnema, Mark‐David Levin, Blood Advances Hematological MalignancyMedicineImmunologyTumor ImmunityImmune Checkpoint Inhibitor	2021	40
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies Christie P.M. Verkleij, Amy Jhatakia, Marloes E.C. Broekmans, Cancers	2020	35
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma Christie P.M. Verkleij, Kristine A. Frerichs, Marloes E.C. Broekmans, HemaSphere	2023	32
T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma Christie P.M. Verkleij, Kristine A. Frerichs, Marloes E.C. Broekmans, Oncotarget	2020	31
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity Ida H. Hiemstra, Kim C. M. Santegoets, Maarten L. Janmaat, EBioMedicine	2023	24

Page 1